Menu Search
Equities

Pro-Dex Inc

PDEX:NAQ

Pro-Dex Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)27.25
  • Today's Change-0.37 / -1.34%
  • Shares traded4.42k
  • 1 Year change+72.47%
  • Beta0.3576
Data delayed at least 15 minutes, as of Sep 20 2024 15:56 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Pro-Dex Inc had net income fall -69.93% from 7.07m to 2.13m despite a 16.83% increase in revenues from 46.09m to 53.84m. An increase in the cost of goods sold as a percentage of sales from 72.34% to 72.98% was a component in the falling net income despite rising revenues.
Gross margin27.02%
Net profit margin3.95%
Operating margin13.32%
Return on assets4.08%
Return on equity6.81%
Return on investment5.20%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Pro-Dex Inc fell by 305.00k. However, the company earned 6.20m from its operations for a Cash Flow Margin of 11.51%. In addition the company used 2.23m on investing activities and also paid 4.27m in financing cash flows.
Cash flow per share0.9288
Price/Cash flow per share28.22
Book value per share9.18
Tangible book value per share9.16
More ▼

Balance sheet in USDView more

Pro-Dex Inc has a Debt to Total Capital ratio of 27.84%, a lower figure than the previous year's 28.21%.
Current ratio2.84
Quick ratio1.66
Total debt/total equity0.3859
Total debt/total capital0.2784
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -69.38%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
EPS growth(5 years)-9.17
EPS (TTM) vs
TTM 1 year ago		-76.52
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.